articleThe LancetNov 1, 2019BRONZE OA

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

HHHarry HeijermanEFEdward F. McKoneDDD.G. DowneyEVEva Van BraeckelSMSteven M. Rowe

University Medical Center Utrecht · University College Dublin · +16 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,348
total citations
FWCI
105.16
Percentile
100%
References
29
Citations per year

Authors

65

Topics & keywords

Topics
Keywords
  • Ivacaftor
  • Cystic fibrosis
  • Regimen
  • Medicine
  • Double blind
  • Internal medicine
  • Mutation
  • Clinical trial
No related works found for this paper.

Funding